Trimebutine - Labopharm

Drug Profile

Trimebutine - Labopharm

Alternative Names: Modulon SR; Trimebutine maleate

Latest Information Update: 10 Oct 2011

Price : $50

At a glance

  • Originator Axcan Pharma; Labopharm
  • Developer Labopharm
  • Class Antispasmodics; Benzoic acids; Gastrokinetics; Irritable bowel syndrome therapies
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 01 Sep 2004 Discontinued - Phase-I for Irritable bowel syndrome in Canada (PO)
  • 26 Sep 2002 Phase-I clinical trials in Irritable bowel syndrome in Canada (unspecified route)
  • 24 Jul 2002 Labopharm and Axcan have signed a letter of intent on a global licensing agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top